canada clinical guidance

Bacterial vaginosis (BV)

A Canadian clinical summary of bacterial vaginosis (bv), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC vulvovaginitis

Source-attributed clinical priorities

  • Confirm a compatible vaginal-discharge syndrome and assess candidiasis, trichomoniasis, cervicitis, retained foreign body and pregnancy.
  • Treat symptomatic bacterial vaginosis with the current Canadian regimen and counsel about recurrence and medication precautions.
  • Offer appropriate STI testing based on exposure and local epidemiology; routine partner treatment is not automatically indicated.
  • A positive molecular result without compatible symptoms does not always require treatment.
sources for this section:SOGC vulvovaginitis

Practical assessment and management workflow

1
Describe discharge, odour, itch, pain, bleeding, pregnancy and STI exposure.
2
Examine and test vaginal pH, microscopy or an approved assay where diagnosis is uncertain.
3
Treat symptomatic disease with a Canadian regimen and counsel about expected recurrence.
4
Reassess persistent symptoms for candidiasis, trichomoniasis, cervicitis or noninfectious vaginitis.
sources for this section:SOGC vulvovaginitis

Safety, red flags and urgent escalation

  • Pelvic pain, fever, pregnancy complication or systemic illness needs assessment beyond uncomplicated vaginosis.
  • Do not recommend douching because it can disrupt vaginal flora.
  • Review medicine interactions and pregnancy considerations before treatment.
sources for this section:SOGC vulvovaginitis

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC vulvovaginitis

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC vulvovaginitis

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Society of Obstetricians and Gynaecologists of CanadaVulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosisaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.